Study of UK Adults With Congenital Adrenal Hyperplasia. (CaHASE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00749593|
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : June 11, 2012
Congenital Adrenal Hyperplasia (CAH) is one of the commonest inherited diseases, affecting 1:14,200 live births. It is the result of a genetic defect in one of the enzymes (in most cases 21-hydroxylase) required for cortisol biosynthesis, leading to reduced levels of cortisol and aldosterone, increased ACTH concentrations and consequently increased adrenal androgen production. Patients suffer from problems with growth and development and as adults patients may have problems with fertility, virilisation in women, testicular masses in men and both men and women have an impaired quality of life. Patients have to take life-long therapy. Despite its frequency knowledge surrounding the management of adults with CAH remains fairly limited. There has been a lot of work describing the management of children with CAH but to date there is no consensus on how to manage adults. To address this issue a number of adult endocrinologists in the UK under the auspices of the Society for Endocrinology have established a country wide study (CaHASE) to undertake research in order to set standards of care for adult patients with CAH.
In CAH the severity of the symptoms experienced by affected individuals varies depending on the mutation and the genetic background of the individual. The ability to tailor CAH therapy on an individual basis, as determined by the severity of the underlying defect and an understanding of the likely natural history of the disease, is a key goal in clinical management. Correlation of phenotype (clinical status) and genotype (the underlying 21 hydroxylase gene mutation) will facilitate stratification of severity and provide an important contribution to the debate on potential mechanisms of individualised therapy. For instance it may become clear that certain CAH genotypes are associated with specific long term outcomes. In time, this could lead to suggesting different treatment strategies in certain groups. Moreover, genotype data are important if we are to address the relative contribution of environment (e.g. treatment) vs. genetics on long term outcomes.
This multi-centre study aims to:
- - Investigate the medical health of adults with congenital adrenal hyperplasia.
- - Investigate the relationship between the genotype of the patient and the phenotype.
- - Investigate the quality of life of adults with congenital adrenal hyperplasia.
|Condition or disease|
|Congenital Adrenal Hyperplasia|
|Study Type :||Observational|
|Actual Enrollment :||25 participants|
|Official Title:||Cross-Sectional Multi-Centre Study of UK Adults With Congenital Adrenal Hyperplasia.|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||June 2007|
|Actual Study Completion Date :||December 2011|
Adults with CAH
- The anthropometric, metabolic, endocrine and quality of life variables of adults with congenital adrenal Hyperplasia will be compared to reference ranges for the normal population. [ Time Frame: End of Study ]
- To identify areas where further research is required and to inform on the day to day management of adults with CAH [ Time Frame: End of study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00749593
|Sheffield Teaching Hospital NHS Foundation Trust|
|Sheffield, United Kingdom, S10 2JF|
|Study Chair:||Richard JM Ross, MD||Sheffield Teaching Hospitals NHS Foundation Trust|